The shares of medmix AG – chief in high-precision supply gadgets in healthcare, industrial and shopper end-markets – had been traded at SIX for the primary time right now.
The spin-off from Swiss industrial group Sulzer was accomplished via a demerger whereas current Sulzer shareholders obtained one medmix share along with every Sulzer share held.
The corporate’s current issued share capital comprised of 34,262,370 registered shares. As well as, 7,000,000 newly issued registered shares had been provided and positioned.
At a difficulty value of CHF 45.00 per registered share, the position quantity was CHF 315 million. Such newly issued registered shares will begin buying and selling on 1 October 2021.
Girts Cimermans, CEO medmix, says: “I want to thank the medmix and Sulzer groups for his or her mixed efforts in making medmix’s incorporation and itemizing such an ideal success. We’re extraordinarily glad to see the belief and enthusiasm that the market and our traders have positioned in us for medmix’s new starting as an impartial firm.
We stay up for constructing on what we have now achieved thus far to proceed medmix’s profitable growth with renewed deal with our core markets and our loyal prospects.”
Jos Dijsselhof, CEO SIX, says: “I’m happy to welcome medmix AG to SIX.
This itemizing provides one other international market chief in its subject to our alternate and additional will increase our peer group of listed firms from the commercial sector. We want medmix AG each success as a SIX-listed firm.”